Table 2.

Anthelminthic activity.

Compounds	5 mg/mL		2.5 mg/mL		1.25 mg/mL
	Paralysis time (min)	Death time (min)	Paralysis time (min)	Death time (min)	Paralysis time (min)	Death time (min)
Negative control (DMSO)	—	—	—	—	—	—
Piperazine citrate	9	10	11	13	24	27
A1	44 ± 2.84	52 ± 2.02	74 ± 1.73	106 ± 2.08	114 ± 2.64	136 ± 1.52
A2	74 ± 0.88	116 ± 0.88	206 ± 3.7	259 ± 1.73	250 ± 1.45	320 ± 2.08
A3	23 ± 2.90	25 ± 2.64	35 ± 3.00	49 ± 2.02	47 ± 1.45	55 ± 0.60
A4	26 ± 0.66	27 ± 0.41	46 ± 1.45	49 ± 1.46	61 ± 0.57	62 ± 2.02
B1	18 ± 0.44	69 ± 2.02	32 ± 1.96	98 ± 2.08	34 ± 0.33	108 ± 0.88
B2	24 ± 0.59	73 ± 1.45	29 ± 1.17	99 ± 1.76	50 ± 2.52	118 ± 2.3
B3	30 ± 0.88	39 ± 1.76	35 ± 0.57	42 ± 2.08	37 ± 0.88	45 ± 2.08
B4	32 ± 0.88	35 ± 0.08	33 ± 0.88	37 ± 1.17	36 ± 0.57	39 ± 0.41

Results are given in mean ± SEM and analyzed by ANOVA ^∗p value < 0.05 compared to standard drug.